RESULTS	The proportion of patients with > or = 15 % relative increase from baseline FEV1 ( satisfactory response ) at day 7 was 62 % for the meropenem/tobramycin group and 44 % for the ceftazidime/tobramycin group ( p = 0.04 ) .\